ARTA
ONCT

A.R.T. Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

A.R.T. Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-490
Closed -$54K – 1693
2018
Q4 		$54K Buy
+490
New +$98K ﹤0.01% 1213

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

A.R.T. Advisors's ONCT Position: Q1 2019 in Review

A.R.T. Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2019, closing a stake of 490 shares — an estimated $54K sold.

A.R.T. Advisors first reported a position in ONCT in Q4 2018 and held it in 1 quarter. The position peaked at $54K in Q4 2018. 35 funds tracked by Wall St. Rank hold ONCT as of Q1 2019.

  • A.R.T. Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 490 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $54K.
  • A.R.T. Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • A.R.T. Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $54K in Q4 2018.
  • 35 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2019.

Based on A.R.T. Advisors's 13F filing for Q1 2019, filed 15 May 2019.